1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Audentes Therapeutics Acquires Cardiogen Sciences

M&A Deal Summary

Audentes Therapeutics Acquires Cardiogen Sciences

On September 1, 2015, Audentes Therapeutics acquired life science company Cardiogen Sciences

Acquisition Highlights
  • This is Audentes Therapeutics’ 1st transaction in the Life Science sector.
  • This is Audentes Therapeutics’ 1st transaction in the United States.
  • This is Audentes Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2015-09-01
Target Cardiogen Sciences
Sector Life Science
Buyer(s) Audentes Therapeutics
Deal Type Add-on Acquisition

Target

Cardiogen Sciences

Palo Alto, California, United States
Cardiogen Sciences, Inc. is a biotechnology company focused on the discovery and development of adeno-associated virus (AAV) gene therapy products for rare, inherited arrhythmogenic diseases.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Audentes Therapeutics

San Francisco, California, United States
Category Company
Founded 2012
Sector Life Science
Employees207
Revenue 134M USD (2018)
DESCRIPTION

Audentes Therapeutics, Inc. is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of AAV gene therapy technology. Audentes Therapeutics was founded in 2012 and is based in San Francisco, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal